Receptor News and Research

RSS

Scientists identify signaling pathway and receptor for thymosin beta 4

RegeneRx Biopharmaceuticals, Inc. nnounced that scientists have identified a long sought-after extracellular signaling pathway and receptor for thymosin beta 4 (Tβ4). The observation that Tβ4 increases cell surface ATP (energy produced by cells), could explain its ability to protect and regenerate tissue after ischemic injury and hypoxia (oxygen deficiency).

30 Nov 2010

CAMH neuroscientists develop novel protein peptide for targeted treatment of depression

Neuroscientists at the Centre for Addiction and Mental Health (CAMH) have developed a protein peptide that may be a novel type of highly targeted treatment for depression with a low side-effect profile. Depression affects one in ten Canadians at some time in their lives and is a leading cause of disability worldwide.

30 Nov 2010

Molecular switch plays crucial role in addictive behavior and memory processes

Learning and memory formation are based on the creation of new connections between neurons in the brain. Also, behaviors such as nicotine addiction manifest themselves in long-term changes of neuronal connectivity and can - at least in this respect - be viewed as a form of learning.

30 Nov 2010

Medivation, Astellas enroll 1,199 patients in MDV3100 Phase 3 AFFIRM study in advanced prostate cancer

Medivation, Inc. and Astellas Pharma Inc. today announced that patient enrollment was completed on November 15, 2010 in the Phase 3 AFFIRM study of the investigational drug MDV3100, a novel, triple-acting oral androgen receptor antagonist, in patients with advanced prostate cancer who have previously been treated with chemotherapy. The companies also announced that clinical development of MDV3100 in Japan has commenced, with the initiation of patient dosing in a Phase 1-2 clinical study.

30 Nov 2010

Calistoga to feature data on CAL-101 inhibitor for hematologic malignancies at ASH Annual Meeting

Calistoga Pharmaceuticals, Inc., the leader in the development of delta-isoform-selective phosphatidylinositol 3-kinase (PI3K-delta) inhibitors for the treatment of cancer and inflammatory diseases, today announced the upcoming presentation of clinical and preclinical results supporting the clinical benefit of CAL-101, an oral, PI3K-delta inhibitor, in the treatment of patients with hematologic malignancies.

30 Nov 2010

Scientists discover M3-protein can help maintain blood sugar levels

Medical scientists at the University of Leicester have identified for the first time a new way in which our body controls the levels of sugar in our blood following a meal.

30 Nov 2010

Transgenomic signs definitive agreement to acquire diagnostic business of Clinical Data

Transgenomic, Inc. announced today the signing of a definitive agreement for Transgenomic to acquire the diagnostic business of Clinical Data, Inc. This acquisition includes a suite of proprietary genetic commercial tests, certain proprietary biomarker assays, and the CLIA-certified laboratory operations of Clinical Data for a purchase price of approximately $15.4 million, primarily in cash and notes.

29 Nov 2010

Superantigens can disrupt immune system, can cause more illnesses

Superantigens, the toxins produced by staphylococcus bacteria, are more complex than previously believed, reveals a team of researchers from the University of Gothenburg in an article published today in the scientific journal Nature Communications. Their discovery shows that the body's immune system can cause more illnesses than realised.

29 Nov 2010

New strategy to prevent memory deficits in mouse model with AD

Scientists at the Gladstone Institute of Neurological Disease (GIND) in San Francisco have discovered a new strategy to prevent memory deficits in a mouse model of Alzheimer's disease (AD).

28 Nov 2010

Looking back and moving forward: 100 years of Pneumococcal vaccination

"Since the introduction of smallpox vaccination by Sir Edward Jenner in 1796, it took 184 years until the WHO could declare the world free of smallpox. How long will it take to eliminate pneumococcus from the world?"

25 Nov 2010

Response to PLX4032 drug short lived in BRAF-mutated metastatic melanoma patients

Researchers with UCLA's Jonsson Comprehensive Cancer Center have found that melanoma patients whose cancers are caused by mutation of the BRAF gene become resistant to a promising targeted treatment through another genetic mutation or the overexpression of a cell surface protein, both driving survival of the cancer and accounting for relapse.

25 Nov 2010

Plant-derived bioscavenger protects against pesticide and nerve agent organophosphate poisoning

The brain is forever chattering to itself, via electrical impulses sent along its hard-wired neuronal "Ethernet." These e-messages are translated into chemical transmissions, allowing communication across the narrow cleft separating one neuron from another or between neurons and their target cells. Of the many kinds of molecules involved in this lively chemical symposium, acetylcholine is among the most critical, performing a host of functions in the central and peripheral nervous system.

24 Nov 2010

Blocking miR-375 microRNA in ERalha-positive breast cancer cells slows down cancer cell growth

Two thirds of breast cancers are ERalpha-positive, i.e., many estrogen receptors of the ERalpha- type are found in their cells. "These molecules can interact with the estrogen hormone and, thus, even lead to cancer," explains Dr. Joerg Hoheisel; molecular biologist at DKFZ. "The connection between the levels of the estrogen receptor alpha and the occurrence of breast cancer has been known for some time now.

24 Nov 2010

Bacterial study confirms TLR2 signaling vital for activating human airway epithelial cells

Researchers from the Boston University School of Medicine (BUSM) have demonstrated that commensal species of the genus Neisseriae are low inducers of human airway epithelial cell responses as compared to the pathogenic species.

24 Nov 2010

Erbitux development program featured in ASCO's Clinical Cancer Advances report for third consecutive year

For the third year in a row, the American Society of Clinical Oncology (ASCO) has included Erbitux® (cetuximab) research in its annual report, Clinical Cancer Advances, which features the most significant studies of 2010. The report cites as a notable advance this year the finding that BRAF mutation status is a prognostic, not predictive, marker for Erbitux efficacy in metastatic colorectal cancer (mCRC).

23 Nov 2010

Neurocrine announces results from elagolix Phase II Daisy PETAL study in endometriosis

Neurocrine Biosciences, Inc. today announced results from the open-label portion of the six month Phase II Daisy PETAL study (901 study) using its proprietary, orally-active nonpeptide Gonadotropin-Releasing Hormone (GnRH) receptor antagonist, elagolix, in patients with endometriosis.

22 Nov 2010

Interim results from H.P. Acthar Gel study in patients with advanced diabetic nephropathy

On November 20 at the American Society of Nephrology 43rd Annual Meeting, interim results presented from an ongoing, randomized prospective study conducted independently by James A. Tumlin, MD, at the University of Tennessee College of Medicine Chattanooga indicated that 9 of 15 patients (60%) with advanced diabetic nephropathy who are currently enrolled in the study and have completed or are still undergoing a six month course of treatment with H.P. Acthar ® Gel have exhibited a clinically significant decrease in proteinuria and achieved stabilized renal function.

22 Nov 2010

Celldex presents ACT III Phase 2 clinical trial data for glioblastoma multiforme at SNO Meeting

Celldex Therapeutics, Inc., today announced the presentation of complete data for the primary endpoint of ACT III, a multi-center, single arm, Phase 2 clinical trial of rindopepimut (CDX-110) in patients with newly diagnosed glioblastoma multiforme (GBM).

21 Nov 2010

Scientists discover Notch pathway may play a role in alcohol's protective effects

Many studies support the assertion that moderate drinking is beneficial when it comes to cardiovascular health, and for the first time scientists have discovered that a well-known molecule, called Notch, may be behind alcohol's protective effects. Down the road, this finding could help scientists create a new treatment for heart disease that mimics the beneficial influence of modest alcohol consumption.

20 Nov 2010

PROTOX closes first tranche of investment by Warburg Pincus

Protox Therapeutics Inc., a leader in the development of receptor targeted therapeutic fusion proteins, today announced it has closed the first tranche of the investment by Warburg Pincus. The investment was approved by 100% of the votes cast by shareholders at the recent special shareholders meeting.

20 Nov 2010

Receptor News and Research

Scientists identify signaling pathway and receptor for thymosin beta 4

CAMH neuroscientists develop novel protein peptide for targeted treatment of depression

Molecular switch plays crucial role in addictive behavior and memory processes

Medivation, Astellas enroll 1,199 patients in MDV3100 Phase 3 AFFIRM study in advanced prostate cancer

Calistoga to feature data on CAL-101 inhibitor for hematologic malignancies at ASH Annual Meeting

Scientists discover M3-protein can help maintain blood sugar levels

Transgenomic signs definitive agreement to acquire diagnostic business of Clinical Data

Superantigens can disrupt immune system, can cause more illnesses

New strategy to prevent memory deficits in mouse model with AD

Looking back and moving forward: 100 years of Pneumococcal vaccination

Response to PLX4032 drug short lived in BRAF-mutated metastatic melanoma patients

Plant-derived bioscavenger protects against pesticide and nerve agent organophosphate poisoning

Blocking miR-375 microRNA in ERalha-positive breast cancer cells slows down cancer cell growth

Bacterial study confirms TLR2 signaling vital for activating human airway epithelial cells

Erbitux development program featured in ASCO's Clinical Cancer Advances report for third consecutive year

Neurocrine announces results from elagolix Phase II Daisy PETAL study in endometriosis

Interim results from H.P. Acthar Gel study in patients with advanced diabetic nephropathy

Celldex presents ACT III Phase 2 clinical trial data for glioblastoma multiforme at SNO Meeting

Scientists discover Notch pathway may play a role in alcohol's protective effects

PROTOX closes first tranche of investment by Warburg Pincus

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News